Although the treatment paradigm for metastatic melanoma has shifted with the use of anti-PD-1 checkpoint inhibitors alone or in combination with ipilimumab, ipilimumab monotherapy may still be a consideration, such as in the treatment of particular patient subgroups following failure of anti-PD-1 therapy.16 In this study, in patients with wild-type BRAF tumors, long-term survival with ipilimumab at either dose was similar to that of the overall population, and patients with BRAF mutations also benefitted from ipilimumab therapy. The gene discussed is BRAF; the disease is metastatic melanoma.